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Abstract
Background: Respiratory Distress Syndrome (RDS) is a prematurity-related breathing disorder caused by a
quantitative deficiency of pulmonary surfactant. Surfactant replacement therapy is effective for RDS newborns,
although treatment failure has been reported. The aim of this study is to trace exogenous surfactant by 13C
variation and estimate the amount reaching the lungs at different doses of the drug.
Methods: Forty-four surfactant-depleted rabbits were obtained by serial bronchoalveolar lavages (BALs), that were
merged into a pool (BAL pool) for each animal. Rabbits were in nasal continuous positive airway pressure and treated
with 0, 25, 50, 100 or 200mg/kg of poractant alfa by InSurE. After 90min, rabbits were depleted again and a new pool
(BAL end experiment) was collected. Disaturated-phosphatidylcholine (DSPC) was measured by gas chromatography.
DSPC-Palmitic acid (PA) 13C/12C was analyzed by isotope ratio mass spectrometry. One-way non-parametric ANOVA
and post-hoc Dunn’s multiple comparison were used to assess differences among experimental groups.
Results: Based on DSPC-PA 13C/12C in BAL pool and BAL end experiment, the estimated amount of exogenous
surfactant ranged from 61 to 87% in dose-dependent way (p < 0.0001) in animals treated with 25 up to 200mg/kg.
Surfactant administration stimulated endogenous surfactant secretion. The percentage of drug recovered from lungs
did not depend on the administered dose and accounted for 31% [24–40] of dose.
Conclusions: We reported a risk-free method to trace exogenous surfactant in vivo. It could be a valuable tool for
assessing, alongside the physiological response, the delivery efficiency of surfactant administration techniques.
Keywords: Respiratory distress syndrome, Lung surfactant, Surfactant replacement therapy, 13C natural abundance,
Stable isotope
Background
RDS is a respiratory disorder that mostly affects
preterm infants and it is characterised by lung immaturity
and critically low amounts of pulmonary surfactant [1, 2].
To overcome pulmonary surfactant deficiency, exogenous
surfactant replacement therapy represents a crucial
achievement in the care of the preterm newborn [3], redu-
cing death and pneumothorax [4]. There are several mo-
dalities to administer exogenous surfactant, including
InSurE (Intubation-Surfactant-Extubation) [5], aerosoliza-
tion [6], laryngeal mask [7], and intratracheal catheters
[8]. Among these, InSurE procedure has been widely used
since it has been shown to improve gas exchange and sur-
vival, and to reduce the duration of mechanical ventila-
tion. However, treatment failure after InSurE has been
reported to be from 9 to 50% [9], with the need of repeat-
ing the treatment in some patients [10].
During clinical development of a therapy, definition of
the dosage and dosage schedule is a key question, and it
is the objective of the so-called dose-finding studies. [11]
Although the performance of a therapy can be evaluated
by different clinical parameters, monitoring the fate of a
drug in vivo remains a main concern, since it usually en-
tails the need for dispensing labelled compounds [12].
The possibility of estimating the amount of drug reach-
ing the target organ could improve treatment dosing
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strategies, help in comparing different delivery systems,
thus increasing the therapy success rate.
We recently developed a new method to estimate
the contribution of exogenous surfactant to the alveo-
lar pool in a rabbit model of RDS based on carbon
stable isotope natural abundance of the disaturated-
phosphatidylcholine palmitic acid (DSPC-PA) [13], the
main phospholipid component of pulmonary surfac-
tant. Briefly, we verified the suitability of our method
in lung-lavaged adult rabbits by assessing the con-
stancy of poractant alfa DSPC-PA carbon stable iso-
topes ratio among different batches, the difference in
carbon stable isotopes abundance between endogen-
ous and exogenous surfactant, and the effect of por-
actant alfa administration on rabbit alveolar DSPC-PA
13C content. Our novel method allowed to discrimin-
ate an endogenous/exogenous (and vice versa) ratio of
1/49 (2%), without the need for dispensing any artifi-
cially labelled compound [14, 15]. This aspect makes
the stable isotope natural abundance approach safe
and exploitable to study in vivo different doses and
surfactant administration methods.
In the present work, we further investigated the effi-
cacy and the reliability of our method in lung-lavaged
adult rabbits managed with a nasal continuous positive
airway pressure [16] (nCPAP) and treated with increas-
ing doses of poractant alfa in a dose-ranging study.
Materials and methods
Animals and sample collection
The experimental procedure was approved by the intra-
mural Animal Welfare Body and the Italian Ministry of
Health (Prot. n° 1300–2015-PR) and complied with the
European and Italian regulations for animal care. A total
of 44 adult rabbits were included in the study. Rabbits
(male) were 7 to 8 weeks old, with a body weight of
1.9 ± 0.3 kg (min 1.2, max 2.8 Kg). Water and diet were
provided ad libitum. The diet was the same for all ani-
mals (3409 Rabbit, maintenance and breeding - Kliba
Nafag, Kaiseraugst, Switzerland) and was kept constant
for at least six days before the studies.
All rabbits underwent a standardized surfactant deple-
tion procedure, using 20mL/kg of pre-warmed saline
(37 °C) until visual inspection showed transparent lavage
fluid, as previously described [16].
For each rabbit, the entire volume of all bronchoal-
veolar lavages (BALs) necessary for surfactant
depletion was pooled (BAL pool). After surfactant de-
pletion, rabbits were randomly assigned to 5 treat-
ment groups and received different doses of poractant
alfa using the InSurE technique according to a pro-
cedure previously described [16]: 0 mg/kg (N = 11); 25
mg/kg (N = 6); 50 mg/kg (N = 11); 100 mg/kg (N = 8);
200 mg/kg (N = 8).
The dose-range 50–200 mg/kg was previously used to
assess the performances of poractant alfa [17] and syn-
thetic surfactant CHF5633 [18].
Ninety minutes after exogenous surfactant administra-
tion, all rabbits underwent a second surfactant depletion
with the same technique as described above. For each
animal, all BALs performed at the end of the experiment
were pooled (BAL end experiment).
After homogenization, a 10-mL aliquot of the BAL
pool and of BAL end experiment was immediately cen-
trifuged at 100×g for 10 min in order to sediment cells
and debris. The supernatant was transferred in a new
tube, aliquoted and stored at − 80 °C until analysis.
Aliquots of all the lots of poractant alfa used for the
study were provided by Chiesi Farmaceutici (Parma,
Italy) and kept at 4 °C until analysis.
Extraction and isolation of DSPC
BALs were slowly thawed on ice, then homogenised by
vortex for 10 s. Lipids were extracted by the method of
Bligh and Dyer [19] after addition of the internal stand-
ard, dipentadecanoyl phosphatidylcholine (PC-C15) 1
mg/ml. Extracted lipids were oxidized with osmium tet-
roxide, resuspended in chloroform and spotted on silica
gel G thin-layer plates (Merck, Darmstadt, Germany).
The plates were developed with chloroform:methanol:
isopropanol:0.25% KCl:trimethylamine (40:12:33:8:24).
DSPC was visualized against a standard and scraped
off from the silica gel plate. DSPC saturated fatty acids
were derivatized as methyl ester by adding 2-mL 3M
HCl methanol and heating at 100 °C for 1 h. Methyl es-
ters were then extracted with hexane.
Poractant alfa aliquots were heated at 37 °C in a water
bath, then diluted 1:81 with NaCl 0.9%, processed and
analysed in triplicate by following the same procedure
used for BAL lipids extraction.
Stable isotopes analysis
In order to assess DSPC concentration, a prior quantitative
analysis of DSPC was performed by Gas Chromatography -
Flame Ionization Detector (GC-FID, HP 5890, Agilent
Technologies, Santa Clara, CA, USA). DSPC-PA 13C/12C
ratio was analysed by Gas chromatography – Combustion
– Isotope Ratio Mass Spectrometry (GC-C-IRMS, Delta V
Advantage, Thermo Fisher Scientific, Waltham, MA, USA).
For GC-C-IRMS analysis, the DSPC fatty acids separ-
ation was achieved on an Ultra-2 (25 m, 0.32 mm, 0.52-
μm film thickness) column (Agilent). Helium was used
as carrier gas, and on-column injection was applied. The
initial temperature gradient was 60 °C, 1-min hold; then
increased to 195 °C with a rate of 30 °C/minute, 2-min
hold; finally, 30 °C/min to 240 °C, with a hold of 7 min.
Fatty acids were then combusted online at 960 °C and
introduced as CO2 into the ion source. Finally, the
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13C/12C ratio of the ionized CO2 was measured by de-
tecting mass 44/45.
Carbon isotopic analysis was performed in triplicate
and normalized against Vienna Pee Dee Belemnite
(V-PDB) standard. Results are expressed as δ‰ (delta
per-mil) of 13C/12C, which indicate the difference, in
part per thousand, from the standard:
δX ‰ð Þ ¼ R sample−R standard
R standard
1000
where “R” is the ratio of the heavy to light isotope in
the sample or standard.
Calculations
Data analysis was carried out with Microsoft Excel 2016
(Microsoft Corp). The contribution of exogenous surfac-
tant to the alveolar pool was calculated as follows:
BAL DSPC mg=Kgð Þ
¼ DSPC mg=mlð ÞBAL Volume mlð Þ
Rabbit body weight Kgð Þ
Dilution factor
¼ PA 13C=12C of BAL end experiment−PA 13C=12C of BAL pool
PA 13C=12C of administered DSPC−PA 13C=12C of BAL pool
Exogenous DSPC mg=Kgð Þ
¼ DSPC in BAL end experiment mg=Kgð Þdilution factor
Endogenous DSPC mg=Kgð Þ
¼ Total DSPC in BAL end experiment−exogenous DSPC
%of administered in lungs ¼ administered DSPC x 100
Exogenous DSPC
Data for each lot of administered poractant alfa were
used for the calculations relative to the receiving rabbits.
For rabbits receiving 0 mg/kg of poractant alfa the
DSPC recovered in BAL end experiment was assumed
to be 100% endogenous.
Statistical analysis
Wilcoxon signed rank test was performed to compare
carbon stable isotopes ratio in BAL pool and BAL end
experiment of control rabbits. One-way non-parametric
ANOVA (Kruskal-Wallis) and post-hoc Dunn’s multiple
comparison were used to assess differences among ex-
perimental groups.
Kendall’s Tau-b (τb) coefficient of correlation was used
to measure the degree of association between the dose
administered and changes in DSPC amount and carbon
stable isotopes content in treated rabbits.
Statistical analysis was performed using GraphPad
Prism 5 (GraphPad Software Inc., San Diego, CA, USA)
and SPSS 25 (IBM Corp, Armonk, NY, USA) software. A
p-value < 0.05 was considered significant. Data are pre-
sented as median and interquartile range [IQR] or as
mean ± SD, according to data distribution.
Results
BAL pool and BAL end experiment from 44 rabbits
treated with different doses of poractant alfa were ana-
lysed for DPSC content and DSPC-PA 13C/12C ratio to as-
sess the contribution of exogenous surfactant to the
alveolar pool. The alveolar DSPC content in BAL pool
and BAL end experiment of rabbit experimental groups
are shown in Fig. 1. No differences were found for BAL
pool (p = 0.177), while the DSPC amount in BAL end ex-
periment was significantly different (p < 0.0001) and posi-
tively correlated (τb 0.789, p < 0001) with the dose
administered.
The 13C abundance of alveolar DSPC-PA was constant
during the experiment for rabbits treated with 0 mg/kg
of poractant alfa: BAL pool − 29.1‰ [− 29.5, − 28.8];
BAL end experiment − 29.0‰ [− 29.3, − 28.1] (p = 0.41).
A positive correlation (τb 0.654, p < 0.0001) was found
between the differences in 13C/12C of DSPC-PA in BAL
end experiment and BAL pool and the administered
dose.
Comparison of the difference between DSPC-PA
13C/12C in BAL end experiment and BAL pool in rabbits
treated with different doses of poractant alfa is shown in
Fig. 2. All groups (50 mg/kg 6.9‰ [5.1, 7.6]; 100 mg/kg
6.7‰ [6.0, 8.4]; 200 mg/kg 8.2‰ [7.8, 8.9]), except ani-
mals treated with a dose of 25 mg/kg (6.5‰ [5.4, 6.7]),
significantly differed from rabbits treated with 0 mg/kg
(0.0‰ [− 0.3, 0.8]) (p < 0.0001).
Based on the differences on 13C/12C of alveolar DSPC-
PA in BAL pool and BAL end experiment, the contribu-
tion of exogenous DSPC to the rabbit alveolar pool and
the percentage of administered poractant alfa recovered
from the lungs were calculated in all treated rabbits. The
percentage of administered poractant alfa recovered
from the lungs did not correlate with the administered
dose (p = 0.80) and accounted for 38% [20, 43], 24% [14,
48], 29% [21, 22] and 35% [23, 40] of the dose with 25,
50, 100, and 200mg/kg, respectively.
The mean ratio between endogenous and exogenous
DSPC in the rabbit alveolar pool of the different experi-
mental groups is shown in Fig. 3. The estimated amount
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of exogenous surfactant in the alveolar pool increased in
a dose-dependent way (τb 0.710, p < 0.0001). A signifi-
cantly higher amount was found for 200 mg/kg group
(24.4 mg/kg [19.1, 26.7]) compared to rabbits treated
with 25 mg/kg (3.0 mg/kg [2.5, 3.7], p < 0.001) and 50
mg/kg (4.1 mg/kg [2.7, 8.5], p < 0.001), and for 100mg/
kg group (9.4 mg/kg [8.9, 12.1]) compared to rabbits
treated with 25mg/kg (p < 0.05).
The estimated amount of endogenous surfactant se-
creted into the airways during 90 min after exogenous
surfactant administration was higher in rabbits treated
with 100 mg/kg (4.0 mg/kg [2.2, 4.3]) and 200 mg/kg
(3.8 mg/kg [2.7, 4.6]) than in rabbits receiving 0 mg/kg
of poractant alfa (0.7 mg/kg [0.3, 1.6]) (p < 0.01).
Discussion
In the present study, we showed the feasibility of using
the 13C natural abundance approach to trace exogenous
surfactant (poractant alfa) at progressively increasing
doses in a rabbit model of RDS. To this purpose, we
Fig. 1 Alveolar DSPC amount (mg/kg) in BALs of rabbits treated with different doses of poractant alfa. (a) BAL pool: pool of all depletion BALs; (b)
BAL end experiment: pool of all BALs collected after poractant alfa administration. Data shown as median and interquartile range. Statistical
differences according to Dunn’s multiple comparison: *p < 0.05, ***p < 0.001. Kendall’s correlation for Fig. 1b: τb = 0.789, p < 0001
Fig. 2 Variation of DSPC-PA 13C. Differences between alveolar DSPC-PA13C/12C in BAL end experiment and BAL pool of rabbits treated with
different doses of poractant alfa. BAL pool: pool of all depletion BALs; BAL end experiment: pool of all BALs collected after poractant alfa
administration. Data shown as median and interquartile range. Statistical differences according to Dunn’s multiple comparison: ***p < 0.001.
Kendall’s correlation: τb = 0.654, p < 0001
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verified: the constancy of alveolar DSPC-PA 13C/12C
during the experiment in a group of untreated rabbits
(0 mg/kg dose); the correlation between the dose admin-
istered and changes in alveolar DSPC-PA 13C/12C before
and after treatment with poractant alfa. Since these
premises were satisfied in our model, we calculated the
contribution of poractant alfa to the surfactant alveolar
pool. Dose-dependent studies have been previously pub-
lished for different animal-derived surfactants, including
bovactant (Alveofact, Boehringer-Ingelheim, Ingelheim
am Rhein, Germany) [20] and poractant alfa [17, 18].
However, those studies focused on the clinical effects of
the administered dose and on the performance of the ex-
ogenous surfactant. Data about the amount of drug
reaching the lungs are scarce. Here we investigated the
possibility to estimate the percentage of surfactant deliv-
ered to the lung by InSurE procedure at increasing doses
of the drug. The percentage of administered exogenous
surfactant recovered from the BAL was only 31%. This is
because an important fraction of the administered sur-
factant becomes inaccessible to lavage already at 1 min
after administration [21]. Moreover, the percentage of
recovery was independent from the dose instilled. This
is a crucial result for allowing users to confidently apply
this technique in different surfactant replacement
studies where often different surfactant dosages need to
be compared. There was a positive correlation between
the administered dose and the differences in DSPC-PA
13C/12C before and after treatment. Based on the
multiple comparison test used, significant difference in
the variation of 13C was not reached only for the
comparison between rabbits receiving 0 and 25mg/kg of
surfactant, because the reported p-value is adjusted for
the number of rabbits (11 vs 6, respectively). These data,
taken together, corroborate the power of our method,
highlighting both a standardization of drug administra-
tion and BAL collection procedures on one side and the
sensitiveness of the natural abundance approach to the
dose administered on the other. Of interest, we used
doses of poractant alfa which are much lower than the
recommended dose of 200 mg/kg. We showed the suit-
ability of our method to quantify “rather low” thera-
peutic doses allowing the premises to apply this
approach also for animal studies on new less-invasive
surfactant application (LISA) systems or for aerosolized
or nebulized surfactant administrations, exploiting the
present results as a calibration curve for the total deliv-
ered surfactant dose.
The combination of both quantitative data on DSPC
amount and on carbon modification after treatment re-
sulted in a clear picture of DSPC alveolar pool, which
was a combination of both poractant alfa and new
synthetized and/or secreted DSPC. The possibility to ac-
curately estimate the ratio between the exogenous and
the alveolar DSPC also allowed for the knowledge that a
greater endogenous portion can be detected in rabbits
who underwent therapy (at clinical dosages) compared
to animals who did not receive the drug. The effect of
the administration of exogenous surfactant on the syn-
thesis and secretion of endogenous lung surfactant have
been extensively studied, although the results are still
controversial [22–24]. In vivo studies suggested an en-
hanced synthesis of endogenous surfactant PC both in
rabbits [25, 26] and preterm infants [27], while no
Fig. 3 Estimated contribution of exogenous surfactant. Ratio between exogenous and endogenous DSPC (mg/kg) in the alveolar pool of rabbits
treated with different doses of poractant alfa by InSurE. Data shown as mean. Standard deviation bars refer to the total amount of DSPC. Kendall’s
correlation for the exogenous surfactant dose: τb = 0.710, p < 0.0001
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noticeable effects on the endogenous synthesis have
been described in mice treated with a therapeutic dose
of both synthetic or natural exogenous surfactant [28].
In the present study, a clear dose-dependent tendency
was observed for the comparison of the endogenous
DSPC amount in the alveolar pool among the experi-
mental groups, confirming a stimulation of endogenous
DSPC secretion or synthesis after treatment, mainly
when a therapeutic dose is administered. Of note, the
present study was conducted in adult rabbits thus with
mature lungs and, likely, with normal amounts of intra-
cellular surfactant. Preterm infants with RDS have low
amounts of both alveolar and lung tissue associated sur-
factant and in addition DSPC synthesis is much reduced.
We speculate that endogenous surfactant synthesis/se-
cretion is less likely to occur in preterm infants in the
time frame of our animal studies. Pilot feasibility studies
in preterm infants are ethically acceptable and they need
to be done. Worth of note, in previous reports the con-
tribution of newly synthesized surfactant has been esti-
mated by the use of radio-labelled [24, 29] or stable
isotope-labelled precursors of surfactant phospholipids
[27, 28]. This is the first study in which the exogenous
and endogenous surfactant can be distinguished in the
alveolar pool without the need for administering any ar-
tificially labelled compound. This aspect supports a
higher suitability of our method for research in human
medicine, even for in vivo studies involving a vulnerable
target population like preterm infants.
This approach is non-invasive and risk-free, but stud-
ies in infants carry some limitations. The first is that it
requires patients to be intubated to allow for airways
sampling. Sample collection is not possible in case of
non-invasive surfactant administration techniques, how-
ever the need for reintubation after such techniques was
reported to be as high as 75% [30]. Data on the contri-
bution of exogenous surfactant to the total amount of
surfactant from tracheal aspirates in case of reintubation
after the first surfactant administration is of interest to
clinicians and it may help in understanding the cause of
the respiratory failure. Our method could help in distin-
guishing respiratory (surfactant related) from non-
respiratory causes of CPAP failure, and could provide in-
formation on the endogenous or exogenous origin of the
surfactant deficiency [31]. Our technique has theoretical
limitations as well. One of these could be represented by
the inter-individual variability of 13C content. This ap-
proach is based on a different isotopic background be-
tween the drug and the biological pool. It is well known
that in animal tissues 13C values typically reflect those of
diet [32]. Here we reported a study conducted on rabbits
with a controlled diet. A restriction could be represented
by the inconsistency of carbon stable isotope back-
ground moving from the animal model to infants fed
with variable diets. We have no data on the feasibility of
our method in countries where the 13C dietary abun-
dance of the population is high as this will likely be the
case of countries with high corn-based food consump-
tion [33, 34]. Data collection about intra- and inter-
individual variability of DSPC-PA 13C/12C in infants who
needed intubation are under way.
Despite these limitations, if this method will be proven
to be suitable for clinical applications in human re-
search, this could represent a significant advancement in
surfactant replacement therapy for the treatment of
RDS, especially in extremely low birth weight infants.
Under the premises of an appreciable difference in
stable isotope content between the exogenous compound
and the biological counterpart, and of a constancy of drug
stable isotope content in different lots, this method could
also be extended to other drug therapies.
Conclusion
We demonstrated the reliability of carbon stable isotopes
approach at natural abundance to trace in vivo the fate
of surfactant replacement therapy. Since the adminis-
tered drug behaves as a natural tracer, no other labelled
compound is required. This approach could be a valu-
able tool for assessing, alongside the physiological re-
sponse, the delivery efficiency of different less-invasive
administration techniques in in vivo studies. However,
the feasibility of this approach in infants deserves further
investigations.
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